Nuvation Bio
NUVB
About: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Employees: 278
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
268% more call options, than puts
Call options by funds: $4.67M | Put options by funds: $1.27M
167% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 30
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
20% more capital invested
Capital invested by funds: $365M [Q1] → $439M (+$74.2M) [Q2]
12% more funds holding
Funds holding: 161 [Q1] → 181 (+20) [Q2]
4.65% more ownership
Funds ownership: 61.4% [Q1] → 66.05% (+4.65%) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Wedbush
David Nierengarten
|
$6
|
Outperform
Reiterated
|
8 Sep 2025 |
|
RBC Capital
Leonid Timashev
|
$7
|
Outperform
Maintained
|
8 Aug 2025 |
|
JMP Securities
Silvan Tuerkcan
|
$6
|
Market Outperform
Reiterated
|
25 Jun 2025 |
Financial journalist opinion
Based on 5 articles about NUVB published over the past 30 days
